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The translation to clinical practice of agents or techniques that protect 
against the effect of ischaemia–reperfusion (IR) injury remains one of 
the most challenging areas of research in the field of cardiovascular 
medicine.1–4 This is particularly the case when IR injury follows 
revascularisation for acute MI (AMI). The publication of the combined 
Effect of Remote Ischaemic Conditioning on Clinical Outcomes in ST 
Elevation Myocardial Infarction Patients Undergoing Primary 
Percutaneous Coronary Intervention (CONDI2/ERIC-PPCI) trial, which 
showed that remote ischaemic conditioning (RIC) did not reduce infarct 
size or improve cardiovascular outcomes, was a blow to the most 
promising cardioprotective target in the last few decades.5
This short article will set the scene for this trial, review the results and 
conclusions of the study, and then consider why the field of 
cardioprotection has suffered so many disappointing failures.
The Need for Cardioprotection
Ischaemic heart disease remains the leading non-infective cause of 
morbidity and mortality in the world. Despite the advances in primary 
percutaneous coronary intervention (PPCI) during AMI, studies have 
suggested that up to 50% of the final infarcted territory is viable at the 
point of reperfusion.6,7 This suggests that continuing injury after, and 
attributable to, reperfusion occurs in the ischaemic myocardium. A 
therapy that consistently reduces the infarct size in this setting would 
have the potential to improve survival and reduce morbidity associated 
with AMI. IR injury is associated with recurrent ischaemia in the setting 
of no-reflow syndrome and coronary microvascular injury, heart failure 
secondary to impaired ventricular function, and an increased scar 
burden, which is associated with increased arrhythmia. Although timely 
reperfusion can limit these consequences, many patients are several 
hours into their AMI at the time of presentation. Mechanisms of 
myocardial IR injury are addressed in detail in other reviews.8,9
Ischaemic Conditioning
The history of the field of cardioprotection stretches back more than 30 
years, with extensive literature that is well reviewed elsewhere.10,11 In 
summary, ischaemic preconditioning was first demonstrated by Murry 
et al. when they discovered that a period of transient occlusion, 
followed reperfusion, of a canine coronary artery reduced infarct size 
when the same vessel was later subjected to a more prolonged period 
of ischaemia and reperfusion.12 This effect occurred even when the 
brief period of IR occurred in a different vascular bed, such as a different 
coronary artery, or a remote bed, such as a limb.13 This became known 
as remote ischaemic preconditioning. It was shown to reduce biomarker 
release and improve long-term outcomes when performed during 
elective percutaneous coronary intervention.14
Remote ischaemic preconditioning has a number of characteristics that 
need to be exploited for it to be effective. It is an all or nothing effect, 
likely reflecting a steep dose–response curve, with a trigger threshold 
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required to achieve protection.15 Both the number of cycles and their 
duration have been shown to be important in achieving protection.16 In 
trials where an adequate ‘dose’, usually a number of cycles of ischaemia 
and reperfusion, has not been achieved, there has been no 
cardioprotection. Furthermore, the protection is short-lived, with a 
window of only a few hours during which time the myocardium is 
protected. A second window of protection caused by transcriptional 
changes in the nucleus has also been investigated.17–20
Since remote ischaemic preconditioning was difficult to deliver prior to 
AMI in the clinical setting due to its unpredictable nature, other studies 
have considered whether postconditioning after the event, or delivering 
the conditioning stimulus during ischaemia, prior to reperfusion is of 
benefit. Zhao et al. demonstrated that a postconditioning stimulus, 
administered in the moments after reperfusion, was effective in 
reducing infarct size for patients receiving PPCI for AMI.21 This 
observation suggested that conditioning may be an adjunct to PPCI, 
limiting the impact of IR injury. While this study used a staggered 
reperfusion technique, others have demonstrated that RIC could 
protect the myocardium.22,23
A number of small to medium-sized trials have attempted to confirm 
that RIC trials have shown benefits on surrogate markers for clinical 
outcome, such as infarct size and the myocardial salvage index.24–31 
Others have confirmed benefits in clinical endpoints, such as major 
adverse cardiovascular and cerebrovascular events or mortality.32–34 
More details regarding these randomised trials of ischaemic 
conditioning are shown in Table 1. Despite the abundance of small-
scale studies demonstrating improvement, the practice of RIC did not 
translate into a change in clinical practice within interventional 
cardiology. Ischaemic conditioning in other contexts had been beset by 
a failure to translate into benefit in the largest-scale trials. For example, 
the large Remote Ischaemic Preconditioning for Heart Surgery 
(RIPHeart) and Effect of Remote Preconditioning on Clinical Outcomes 
in Patients Undergoing Coronary Artery Bypass Graft Surgery (ERRICA) 
trials of ischemic conditioning prior to and during elective cardiac 
surgery with cardiopulmonary bypass did not show any evidence of 
improved outcomes.35,36
After these studies, a number of editorials suggested that the failures 
of translation in these studies were at least partially related to the 
effect of the anaesthetic agent, propofol, on the intracellular pathways 
of cardioprotection, as shown by Kottenberg et al., together with trial 
protocols that failed to address the populations most likely to benefit 
from RIC.37–39 Failure to address the biology of cardioprotection has 
been behind the difficulty in translating cardioprotective interventions 
into clinical practice for a long time (Figure 1).1,40–42
The CONDI2/ERIC-PPCI Trial
The CONDI2/ERIC-PPCI trial was a combination of two trials with 
harmonised protocols to carry out single-blind RIC during ST-elevation 
MI (STEMI). The trial randomised 5,401 patients at 33 centres to receive 
either ischaemic conditioning using an automated remote ischaemic 
conditioning device, or a sham procedure. Some centres offered 
standard care rather than the sham. The primary endpoint was 
cardiovascular death or hospitalisation for heart failure at 12 months. 
Secondary endpoints included major adverse cardiovascular and 
cerebrovascular events, and infarct size measured using the area 
under the curve for high-sensitivity troponin T.
The trial found that there were no clinically meaningful differences 
between the RIC group and the control group. The primary outcome 
occurred in 8.6% of the control group and 9.4% of the RIC group 
(treatment effect 1.10, 95% CI [0.91–1.32]; p=0.32) with no significant 
difference in biomarker-assessed infarct size. The cardiac MRI substudy 
is still awaited, but regardless of its findings it is unlikely to provide 
evidence that RIC offers substantial clinical benefit. Other editorial and 
opinion pieces have concluded that the low overall mortality was the 
reason for the failure of the study.43 Certainly, the study was appropriately 
powered for the expected event rate, but one possibility is that the 
patients were simply not unwell enough to see a significant benefit.
These findings are at odds with those of the previously published 
investigations discussed above. However, this study was adequately 
powered to provide a definitive answer, and evaluation of 
the previous literature now needs to be placed in the context of 
this study. Other studies were substantially smaller, with low 
numbers of events, potentially leading to type 1 error. Furthermore, 
publication bias may have favoured those RIC studies with positive 
results. The disappointing results of this trial have left researchers in 
the field looking for alternative targets that can be used to mitigate the 
impact of IR injury.
Alternative Targets for Cardioprotection
A number of potential pharmacological targets have presented 
themselves as alternatives to RIC. These include agents that interact 
with the cascade of biochemical and cellular changes that lead to cell 
death. A comprehensive review of all targets that have been investigated 
is beyond the scope of this review, but many of these have failed to 
translate to clinical practice, because trials have ignored the biology of 
cardioprotection and benefit in vitro, or small animal studies have not 
been replicated in human trials. Table 2 offers some of the reasons for 
the failure of clinical trials.
Adenosine
Binding of the adenosine receptor prior to ischaemia has been shown 
to provide cardioprotection and reduce infarct size. However, 
whether this benefit occurs if adenosine is administered after the onset 
of ischaemia is less clear. While some clinical studies have 
shown a reduction in infarct size and improvement in clinical 
outcome with adenosine, others have been neutral.44–47 These trials 
have been characterised by variability in dose, timing and route of 
Figure 1: The Window of Cardioprotection
The opportunities for cardioprotection around ischaemia and reperfusion are shown. The time 
in which effective therapy can be delivered after reperfusion with percutaneous coronary 
intervention is brief. After this time the window in which patients will benefit is closed.  
GLP-1 = glucagon-like peptide-1; PPCI = primary percutaneous coronary intervention;  
RA = receptor agonist; RIC = remote ischaemic conditioning. Source: Giblett et al. 2014.42 
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administration. A recent meta-analysis suggests there may be a benefit 
for intracoronary adenosine in reducing the incidence of heart failure 
after AMI.48
Glucagon-like Peptide-1
Glucagon-like peptide-1 (GLP-1) is an incretin hormone used as a target 
in the treatment of type 2 diabetes. GLP-1 receptors may provide 
cardioprotection through activation of intracellular pathways, such as 
the reperfusion injury survival kinase and survivor activating factor 
enhancement pathways.49,50 While these pathways share components 
with the pathways of ischaemic conditioning, they are not identical.51 
GLP-1 receptor agonists have been shown to reduce the 
frequency of major adverse cardiovascular and cerebrovascular events 
in high-risk patients with diabetes in some larger cardiovascular 
outcome studies, improve myocardial function after non-lethal IR injury, 
as well as reducing infarct size and improving left ventricular function 
after PPCI in small proof of concept trials.52–57
However, not all trials have shown such benefit. GLP-1 agonists did not 
reduce the frequency of major adverse cardiovascular and 
cerebrovascular events following administration to diabetes patients 
after AMI, nor did they reduce periprocedural MI or cardiac troponin 
release during elective percutaneous coronary intervention.58,59 This 
conflicting evidence suggests the need for a larger and more definitive 
trial to establish benefit
Beta-blockers and Ivabradine
Early administration of beta-blockers has been considered an attractive 
cardioprotective strategy, since cardiologists are familiar with 
administering these agents in this patient group, making translation to 
clinical practice easier if effective. However, there are discrepancies 
between trials of the beta-blocker metoprolol during STEMI. In the 
Effect of Metoprolol in Cardioprotection During an Acute Myocardial 
Infarction (METOCARD-CNIC) study, a large dose of IV metoprolol 
reduced infarct size when administered before reperfusion, whereas in 
the Early Beta-blocker Administration Before Reperfusion in Patients 
with ST-elevation Myocardial Infarction (EARLY-BAMI) trial, a smaller 
dose given to a less selected population had no effect on infarct 
size.60,61 Earlier administration to metoprolol was associated with 
reduced infarct size in a post hoc analysis of METOCARD-CNIC.61 
Furthermore, ivabradine, which acts at the sinoatrial node to reduce 
heart rate, reduced infarct size in a porcine model of IR injury, but when 
given to humans up to 1 hour after PPCI, no benefit was seen.62,63 This 
was likely too late to prevent IR injury.
Dose-finding and timing studies are not routinely undertaken in humans 
in the field of cardioprotection, often leaving more questions than 
answers in the search for protection. The interpretation of these larger 
studies has been confounded by the absence of appropriate early 
studies establishing these characteristics.
Cyclosporine
Cyclosporine A prevents opening the mitochondrial permeability 
transition pore, which is part of the final pathway of cell death in 
reperfusion injury.64 Early trials showed apparent benefit in small 
numbers of patients treated with cyclosporine.65,66 Disappointingly, 
however, the much larger Cyclosporine to Improve Clinical Outcome in 
ST-elevation Myocardial Infarction Patients (CIRCUS) trial failed to show 
any benefit in terms of infarct size or clinical outcomes in patients with 
STEMI.67 This failure has been attributed to a number of different 
factors, including an increased length of ischemic time, a difference in 
the formulation of cyclosporine A and increased use of newer 
antiplatelet agents.9 Nonetheless, cyclosporine A has fallen at the same 
stage of translation as RIC. The definitive randomised control trial was 
neutral in outcome. Other mitochondrial permeability transition pore 
inhibitors have had mixed or neutral results in small proof of concept 
trials or animal studies.68 The mitochondrial permeability transition 
pore may remain a target for cardioprotection with the right agent.
Table 1: The Flaws of Cardioprotective Trials
Flaw Explanation
Timing • Must be administered during ischaemia or first moments of reperfusion to be effective
• Intervention administered after cardioprotective window is closed will not reduce infarct size
• For some interventions, however biologically attractive, timing may be impossible to practically achieve in the setting of AMI
Dose • If the intervention does not achieve the required dose in the ischaemic tissue, it will not be effective
• Careful decisions regarding route and timing of administration are required to ensure biological effects can be exploited
• Animal and small-scale human dose finding studies will aid the design of larger scale trials
Patient selection • Patients with both too little ischaemia and too long an ischaemic time are less likely to benefit from cardioprotective interventions
• Heterogenous groups included in trials (older people and people with diabetes) may have different thresholds of resistance to 
cardioprotection
• Optimising patient recruitment by including more high-risk patients may increase the chance of demonstrating benefit, as the cost 
of reduced applicability of the study to current practice
Animal studies • Interventions with inconsistent effects in animal models need careful consideration before application to large-scale human trials
• Attention to biology demonstrated in these studies, including evidence in larger animal models with physiology more closely 
related to humans, will improve trial design
Concurrent medication • Exclusion of patients on medications likely to reduce the effectiveness of the intervention (such as propofol in CABG RIC trials) may 
increase the chance of demonstrating benefit
Endpoints • Inconsistent use of endpoints between trials make comparison more challenging
• Biomarker endpoints may be consistently reduced with cardioprotective interventions, but these may be of little clinical 
consequence
• Care must be taken when infarct size is corrected for area at risk, particularly when estimation of area at risk can be affected by 
the intervention itself




Yang et al. first demonstrated a direct cardioprotective effect with the 
P2Y12 receptor antagonist cangrelor prior to reperfusion, and showed 
a 30% reduction in MI size in rabbits.69 Crucially, cangrelor was only 
effective at limiting MI size if it was administered prior to reperfusion. 
Cangrelor-mediated cardioprotection (but not platelet inhibition) was 
abrogated by pharmacological inhibitors of phosphoinositide 3-kinase 
and mitogen-activated protein kinase kinase 1/2, both known mediators 
of cardioprotection, suggesting the protective effect of cangrelor was 
independent of antiplatelet effects. 
The cardioprotective effects of P2Y12 inhibitors have also been shown 
using pretreatment with oral ticagrelor in rats, and cangrelor in 
primates.70,71 Furthermore, pretreatment with ticagrelor was also shown 
to reduce MI size in a porcine MI model.72 The Platelet Inhibition to 
Target Reperfusion Injury (PITRI) trial is currently ongoing, and is 
evaluating whether cangrelor administered prior to reperfusion would 
reduce reperfusion injury, as assessed by CMR in 210 patients 
(NCT03102723).73 
Supersaturated Oxygen Therapy
Delivery of supersaturated oxygen with a partial pressure of 750–
1,000 mmHg immediately after reperfusion has been shown to reduce 
anterior myocardial infarct size in the Acute Myocardial Infarction with 
Hyperoxemic Therapy II (AMIHOT-II) trial.74 Furthermore, the IC-HOT 
study demonstrated that it was feasible for supersaturated oxygen to 
be delivered directly to the left main stem during STEMI.75 While the 
TherOx system has been approved by the Food and Drug Administration 
for treatment of AMI, randomised trials have only been conducted in 
relatively small numbers of patients. Similar results have been seen for 
other cardioprotective interventions, which have proven to be 
ineffective in larger or less well selected trials. It is worth noting that in 
AMIHOT-II, only 317 patients out of 2,517 screened with STEMI were 
enrolled, and most of these failures were due to failure to meet 
inclusion criteria. It is uncertain how generalisable this data is to the 
unselected STEMI population. Larger trials in this area are required.
How Can We Do Better with Future 
Targets for Cardioprotection?
Translation in this field has proved beyond challenging. Despite an 
enormous investment of time, money and resources in the search for 
an adjunct to coronary revascularisation to prevent IR injury, no 
candidate therapy has become a part of the armamentarium of the 
interventional cardiologist. It is more than 30 years since the discovery 
of ischaemia preconditioning, but we still wait. Criticisms of decisions 
taken in trials are not new and have been repeated many times. 
Nonetheless, it is worth rehearsing some of the challenges of study 
design, which may provide better direction for future research.
Failure to pay attention to the biology of IR injury, cardioprotection 
and the specific cardioprotective agents under investigation is a key 
factor in many studies. No agent will be effective at reducing infarct 
size if it is delivered too late, or in too small a dose to be effective. 
Table 2: Randomised Trials of Ischaemic Conditioning in Primary Percutaneous Coronary Intervention
Study n Endpoints Results Comments
Botker et al. 201024 333 Myocardial salvage index (MPI) Mean salvage index 0.69 (RIC) versus 0.57 (control), p=0.03RIC
Lonborg et al. 201025 118 Infarct size (CMR) 17% reduction in infarct size as %LV with PostC PostC
Sorrenson et al. 201026 76 Infarct size (CMR) No difference in infarct size for overall group, post hoc 
analysis suggests benefit in patients with large area at risk
PostC
Freixa et al. 201227 79 Myocardial salvage index (CMR) Lower myocardial salvage index in PostC 
group (18.9 ± 27.4 versus 30.9 ± 20.5%, 
p=0.038). No significant difference in infarct size 
or LV ejection fraction
PostC
Zhao et al. 201228 62 LV ejection fraction (Echo) No difference between PostC and control at 
1 week. Improved LV ejection fraction at 6-month 
follow-up in PostC group
PostC
Thuny et al. 201229 50 Infarct size (CMR) Reduced infarct size after PostC (13 ± 7 g/m2 versus  
21 ± 14 g/m2; p=0.01). Note PostC also reduced 
myocardial oedema on CMR, suggesting this may not be 
reliable for area-at-risk calculation
PostC. Note: PostC also reduced 
myocardial oedema on CMR,  
suggesting this may not be reliable  
for area-at-risk calculation
Hahn et al. 201330 
(POST)
700 ST segment resolution at 30 
minutes
No difference between PostC and control in ST segment 
resolution at 30 minutes or MACE 
PostC
Sloth et al. 201432 251 MACE Reduced MACE events with HR 0.49 
(95% CI [0.27–0.89]); p=0.018
All-cause mortality also improved in  
per protocol analysis
White et al. 201531 83 Infarct size (CMR) Reduction in infarct size by 27% (p<0.01) RIC. Also reduced myocardial oedema, 
and myocardial salvage index
Gaspar et al. 201833
(RIC STEMI)
448 Cardiovascular death or heart 
failure hospitalisation at  
long-term follow-up
Reduction in clinical events of composite endpoint 
at follow up (HR 0.35, 95% CI [0.15–0.78])
RIC
Stiermaier et al. 201934 696 MACE Combined RIC and PostC reduced events 
compared to control and PostC alone
1:1:1 randomisation to control, PostC 
alone, or PostC and RIC
Hausenloy et al. 20195 
(CONDI2/ERIC-PPCI)
5,401 Cardiovascular death or heart 
failure hospitalisation at 
12 months
No difference between RIC and control  
(HR 1.10, 95% CI [0.91–1.32], p=0.32)
RIC
CMR = cardiac magnetic resonance; LV = left ventricle; MACE = major adverse cardiovascular events; MPI = myocardial perfusion imaging; PostC = postconditioning; RIC = remote ischaemic 
conditioning; STEMI = ST-elevation MI.
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Small-scale human trials can provide much information in this regard, 
and ideally dose and timing studies should be undertaken with 
appropriately powered surrogates for benefit, before proceeding to 
larger human studies. Careful selection of patients in both small and 
large studies is also key to success. Inclusion of patients who will not 
benefit from the intervention will reduce the power of the study to 
show benefit. This could include patients with both too little ischaemia 
or too long an ischaemic time. Enriching the cohort with patients 
likely to benefit, such as those with anterior infarcts or with moderate 
ischaemic times, will increase the power of the study to show benefit, 
although this may come at the cost of generalisability in the real world 
of clinical practice.
Post hoc analysis of the Botker et al. study suggests that RIC was 
effective in patients with a delayed transfer to a PPCI centre while not 
benefiting those who received more rapid reperfusion.24,76 Furthermore, 
inclusion of older patients, or patients with diabetes, may require 
adjustment of the dosing regimens to increase the likelihood of benefit.
The selection of a single target has been a consistent theme in trials of 
cardioprotection. It is possible that an effective reduction in infarct size 
depends upon accessing multiple pathways of cardioprotection 
simultaneously.77 There may be additive and synergistic effects between 
interrelated pathways, or it may be that in a heterogenous population 
presenting with AMI, different pathways will provide more or less 
effective cardioprotection for a given individual, depending upon 
comorbidities and other patient factors. A large number of animal 
models have been successfully tested, but there have been relatively 
few human trials of this approach reported. Combination Therapy in 
Myocardial Infarction (COMBAT-MI) is an example of a clinical trial 
combining RIC with exenatide infusion to evaluate whether combination 
therapy is more effective (NCT02404376).
Endpoint selection is a key factor in the success of translational studies.9 
Assessment of infarct size using biomarker endpoints, such as cardiac 
troponin, are very sensitive, but unless high thresholds are used, small 
changes in these may be of limited clinical relevance, particularly in the 
context of periprocedural MI.78 Cardiomyocyte-specific creatine kinase 
has been shown to be the most robust biomarker for quantification of 
infarct size, but in clinical practice it has largely been replaced with 
cardiac troponin, which limits its availability for multicentre clinical 
trials.79 Cardiac MRI is an excellent method to quantify infarct size and 
assess cardioprotective strategies used during AMI.80,81 The more 
sensitive myocardial salvage index can be used to increase the power of 
the study, but remains controversial, as T2-weighted imaging is used to 
delineate the oedema-based area at risk.82 The myocardial oedema may 
be impacted by both the timing and nature of the intervention, and the 
timing of the MRI.29,31
New late gadolinium after AMI is a more robust tool to investigate the 
impact of cardioprotection in phase II studies.83 Assessment of the 
microcirculation may also prove to be important. Some retrospective 
evidence suggests that therapies improving microcirculatory function 
after MI may improve clinical outcome independently of the infarct 
size.84 This requires further investigation, and these endpoints 
investigated prospectively.
Clinical endpoints are important, but should reflect the biology of 
cardioprotection. Hard endpoints, such as cardiovascular mortality, are 
important. Endpoints, such as heart failure admission or the need for 
escalation in heart failure medication, are important, as this is the 
syndrome most likely to be impacted by therapies that reduce infarct 
size. They need to be carefully defined, as these are softer clinical 
endpoints that are vulnerable to a number of biases. Endpoints 
commonly used in trials of percutaneous coronary intervention 
strategies and stents, such as the need for repeat revascularisation, 
reduce the power of these studies to show benefit, as they are unlikely 
to be affected by the cardioprotective intervention.
Conclusion
The CONDI2/ERIC-PPCI study was a well-run clinical trial of a potentially 
valuable therapy. Its neutral result leaves behind serious questions for 
the field of cardioprotection; the next avenue that should be pursued in 
a large-scale trial is not altogether clear. The development of 
collaborative groups, such as the European Society of Cardiology 
Working Group on Cellular Biology of the Heart and the EU-
CARDIOPROTECTION COST Action, to push the field forward is welcome, 
and is likely to produce more fruitful translation to clinical practice. 
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